U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07450417) titled 'Effect of Early Empagliflozin Initiation in Cardiogenic Shock.' on March 04, 2025.
Brief Summary: Cardiogenic shock represents a severe condition of heart pump dysfunction. Despite advances in medical management, the mortality rate for this condition remains high. Conventional treatments for cardiovascular diseases have several side effects that make their use impossible in patients with cardiogenic shock.
A new class of drugs has been developed in recent years and is an integral part of the management of patients with chronic heart failure. These are sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors), namely empaglifloz...